Differentiating Autoimmune Hepatitis from Viral Hepatitis
Distinguishing genuine autoimmune hepatitis (AIH) from viral hepatitis with autoimmune features is challenging but critical, as the distinction determines whether immunosuppressive therapy—which could worsen viral control—is warranted. 1
Key Diagnostic Approach
Step 1: Establish Viral Status First
- Screen for viral hepatitis markers (HBsAg, anti-HBc, anti-HCV, HCV RNA, HDV if indicated) in all patients presenting with hepatitis
- This is non-negotiable before considering AIH diagnosis 2
Step 2: Evaluate Autoantibody Patterns
Autoantibody frequency differs significantly between conditions:
- AIH: ANA positive in 96%, SMA positive in 50% 1
- Chronic HDV: ANA positive in 67%, SMA positive in 16% 1
- Chronic HBV: ANA positive in 43%, SMA positive in 3% 1
- Chronic HCV: ANA positive in 26%, SMA positive in 6% 3
Critical distinguishing feature: SMA with F-actin reactivity is detected ONLY in AIH, not in viral hepatitis 1. This is your most specific marker when present.
Step 3: Assess IgG Levels
IgG elevation patterns are highly discriminatory:
- AIH: Median IgG typically >16-18 g/L, often with selective or highly preferential IgG elevation 4
- Chronic HDV: Median IgG 16.9 g/L 1
- Chronic HBV: Median IgG 12.7 g/L 1
In acute presentations: Patients with acute AIH have significantly higher gamma-globulin levels (26.9 g/l) compared to acute viral hepatitis (13.4 g/l, p<0.0001) 5
Step 4: Clinical and Biochemical Clues
Gender: Acute AIH is predominantly female (82% vs 24% in viral hepatitis) 5
AST/ALT ratio: Higher in acute AIH (1.20) versus viral hepatitis (0.61, p<0.0001) 5
Transaminase levels: AIH patients typically have significantly higher transaminase and GLDH levels 3
Step 5: Histological Assessment
Liver biopsy is mandatory but presents challenges:
- No pathognomonic features exist for AIH 1
- Interface hepatitis with plasma cell enrichment suggests AIH but is not specific 2, 4
- Modified HAI score: AIH typically shows mHAI of 9/18, compared to 6.5/18 in HDV and lower in HBV 1
Step 6: Test for SLA Antibodies in Seronegative Cases
- Anti-SLA antibodies are the ONLY specific antibodies for AIH (present in 7-22% of cases) 4
- Found exclusively in autoimmune liver disease, never in viral hepatitis 3
- Should be tested when conventional autoantibodies (ANA, SMA, anti-LKM1) are negative or equivocal 2
Critical Management Decision Point
When viral hepatitis coexists with autoimmune features:
- Start antiviral therapy first (strong recommendation) 1
- Monitor for persistent inflammation after achieving adequate viral control
- Add immunosuppressive therapy ONLY if liver inflammation persists despite viral suppression (strong recommendation) 1
This sequential approach prevents the catastrophic error of immunosuppressing active viral replication.
Common Pitfalls to Avoid
Do not diagnose AIH based solely on:
- Positive ANA or SMA alone—these occur in 19% of HCV and 14% of HBV patients 3
- Elevated transaminases without viral exclusion
- Histology alone without serological correlation
Critical caveat: Approximately 50% of patients with HEV infection have at least one positive autoantibody (33% ANA-positive, 21% SMA-positive), but none developed AIH 1. This underscores that autoantibodies in viral hepatitis represent epiphenomena, not genuine autoimmune disease.
In HCV patients: Oral antiviral treatment resolves autoimmune features, confirming they were virus-associated rather than true AIH 1
Simplified Diagnostic Scoring
For definite AIH diagnosis, you need ≥7 points 4:
- IgG >18 g/L: 2 points (>16 g/L: 1 point)
- ANA/SMA >1:80 or SLA positive: 2 points (>1:40: 1 point)
- Histology typical for AIH: 2 points (compatible: 1 point)
- Viral markers negative: 2 points
This provides >90% positive and negative predictive value for AIH diagnosis 4.